Biophan Technologies Expands Biotechnology Intellectual Property Portfolio to 114 Patents Issued or Filed.

ROCHESTER, N.Y. -- New Patents Further Solidify Company's Control of Key Solutions in Multi-Billion-Dollar Biomedical Markets

Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has announced continued growth of its intellectual property portfolio, reaching a total of 114 issued or filed patents in a range of cutting-edge biomedical fields. The newly-issued patents and recent patent applications claim important additional intellectual property coverage for the Company as it continues its development of advanced solutions for Magnetic Resonance Imaging (MRI) safety and image compatibility for surgical instruments and implanted devices, and other markets.

The Company now holds a total of 34 issued patents, 8 allowed (that is, approved for subsequent issuance), with the remaining 72 undergoing the patent examination process. The latest additions to Biophan's intellectual property portfolio include two newly issued patents and six filed patent applications.

"Biophan has been continuing to aggressively execute its business strategy of protecting its next-generation intellectual property portfolio with broad patents that are designed to provide us control of important biomedical markets," said Michael Weiner, CEO of Biophan. "Our latest issued patents further expand on recently issued patents involving the fields of photonics and nanomagnetic coatings. These technologies can be used to improve safety and visualization in MRI environments and for a new class of drug-eluting applications."

Biophan obtained one of the issued patents through its recent acquisition of AMRIS, an advanced MRI company in Germany that has since been established as Biophan-Europe. Another newly issued patent was granted to Biophan's joint-development partner Nanoset LLC. Biophan holds the exclusive worldwide marketing rights to Nanoset's patents for all medical markets.

The six new patent applications involve several areas, including the Company's ceramic-based, MRI-compatible Squiggle(TM) motor, which it is developing with technology partner New Scale Technologies. Other new patent applications covered key areas in the development of nanomagnetic coatings that are designed to improve visualization and safety of implanted medical devices, such as stents and catheters, within MRI-imaging environments.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 34 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.